159 related articles for article (PubMed ID: 37330328)
1. Accelerated hypofractionated magnetic resonance-guided adaptive radiotherapy for oligoprogressive non-small cell lung cancer.
La Rosa A; Mittauer KE; Chuong MD; Hall MD; Kutuk T; Bassiri N; McCulloch J; Alvarez D; Herrera R; Gutierrez AN; Tolakanahalli R; Mehta MP; Kotecha R
Med Dosim; 2023 Winter; 48(4):238-244. PubMed ID: 37330328
[TBL] [Abstract][Full Text] [Related]
2. Comparison of MR-guided radiotherapy accumulated doses for central lung tumors with non-adaptive and online adaptive proton therapy.
Rabe M; Palacios MA; van Sörnsen de Koste JR; Eze C; Hillbrand M; Belka C; Landry G; Senan S; Kurz C
Med Phys; 2023 May; 50(5):2625-2636. PubMed ID: 36810708
[TBL] [Abstract][Full Text] [Related]
3. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3).
Regnery S; Ristau J; Weykamp F; Hoegen P; Sprengel SD; Paul KM; Buchele C; Klüter S; Rippke C; Renkamp CK; Pohl M; Meis J; Welzel T; Adeberg S; Koerber SA; Debus J; Hörner-Rieber J
Radiat Oncol; 2022 May; 17(1):102. PubMed ID: 35614486
[TBL] [Abstract][Full Text] [Related]
5. Widening the therapeutic window for central and ultra-central thoracic oligometastatic disease with stereotactic MR-guided adaptive radiation therapy (SMART).
Lee G; Han Z; Huynh E; Tjong MC; Cagney DN; Huynh MA; Kann BH; Kozono D; Leeman JE; Singer L; Williams CL; Mak RH
Radiother Oncol; 2024 Jan; 190():110034. PubMed ID: 38030080
[TBL] [Abstract][Full Text] [Related]
6. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
7. In Silico Trial of MR-Guided Midtreatment Adaptive Planning for Hypofractionated Stereotactic Radiation Therapy in Centrally Located Thoracic Tumors.
Henke LE; Kashani R; Hilliard J; DeWees TA; Curcuru A; Przybysz D; Green O; Robinson CG; Bradley JD
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):987-995. PubMed ID: 29953910
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric Comparison of Real-Time MRI-Guided Tri-Cobalt-60 Versus Linear Accelerator-Based Stereotactic Body Radiation Therapy Lung Cancer Plans.
Wojcieszynski AP; Hill PM; Rosenberg SA; Hullett CR; Labby ZE; Paliwal B; Geurts MW; Bayliss RA; Bayouth JE; Harari PM; Bassetti MF; Baschnagel AM
Technol Cancer Res Treat; 2017 Jun; 16(3):366-372. PubMed ID: 28168936
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
10. SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial.
Giuliani M; Mathew AS; Bahig H; Bratman SV; Filion E; Glick D; Louie AV; Raman S; Swaminath A; Warner A; Yau V; Palma D
Clin Lung Cancer; 2018 Jul; 19(4):e529-e532. PubMed ID: 29759332
[TBL] [Abstract][Full Text] [Related]
11. Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience.
Garcia Schüler HI; Pavic M; Mayinger M; Weitkamp N; Chamberlain M; Reiner C; Linsenmeier C; Balermpas P; Krayenbühl J; Guckenberger M; Baumgartl M; Wilke L; Tanadini-Lang S; Andratschke N
Radiat Oncol; 2021 Nov; 16(1):217. PubMed ID: 34775998
[TBL] [Abstract][Full Text] [Related]
12. Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages.
Henke L; Kashani R; Yang D; Zhao T; Green O; Olsen L; Rodriguez V; Wooten HO; Li HH; Hu Y; Bradley J; Robinson C; Parikh P; Michalski J; Mutic S; Olsen JR
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1078-1086. PubMed ID: 27742541
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen.
Henke L; Kashani R; Robinson C; Curcuru A; DeWees T; Bradley J; Green O; Michalski J; Mutic S; Parikh P; Olsen J
Radiother Oncol; 2018 Mar; 126(3):519-526. PubMed ID: 29277446
[TBL] [Abstract][Full Text] [Related]
14. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
[TBL] [Abstract][Full Text] [Related]
15. Comparison of different dose accumulation strategies to estimate organ doses after stereotactic magnetic resonance-guided adaptive radiotherapy.
Regnery S; Leiner L; Buchele C; Hoegen P; Sandrini E; Held T; Deng M; Eichkorn T; Rippke C; Renkamp CK; König L; Lang K; Adeberg S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2023 May; 18(1):92. PubMed ID: 37248504
[TBL] [Abstract][Full Text] [Related]
16. Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors.
Finazzi T; Palacios MA; Spoelstra FOB; Haasbeek CJA; Bruynzeel AME; Slotman BJ; Lagerwaard FJ; Senan S
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):933-941. PubMed ID: 30928360
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: the PUMA trial.
Regnery S; de Colle C; Eze C; Corradini S; Thieke C; Sedlaczek O; Schlemmer HP; Dinkel J; Seith F; Kopp-Schneider A; Gillmann C; Renkamp CK; Landry G; Thorwarth D; Zips D; Belka C; Jäkel O; Debus J; Hörner-Rieber J
Radiat Oncol; 2023 May; 18(1):74. PubMed ID: 37143154
[TBL] [Abstract][Full Text] [Related]
18. Accelerated Hypofractionated Magnetic Resonance Guided Adaptive Radiation Therapy for Ultracentral Lung Tumors.
La Rosa A; Mittauer KE; Bassiri N; Rzepczynski AE; Chuong MD; Yarlagadda S; Kutuk T; McAllister NC; Hall MD; Gutierrez AN; Tolakanahalli R; Mehta MP; Kotecha R
Tomography; 2024 Jan; 10(1):169-180. PubMed ID: 38250959
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
20. Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity.
Breen WG; Jeans EB; Gergelis KR; Garces YI; Park SS; Merrell KW; Peikert TD; Mansfield AS; Wigle DA; Harmsen WS; Ellerbusch DC; Olivier KR; John Lucido J; Owen D
Radiother Oncol; 2021 May; 158():246-252. PubMed ID: 33711411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
